Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more
Zymeworks Inc. Common Stock (ZYME) - Total Liabilities
Latest total liabilities as of September 2025: $77.20 Million USD
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has total liabilities worth $77.20 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zymeworks Inc. Common Stock - Total Liabilities Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zymeworks Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ShenZhen Yitoa Intelligent Control Co Ltd
SHE:300131
|
China | CN¥1.77 Billion |
|
Orpea SA
PINK:ORPEF
|
USA | $11.57 Billion |
|
China First Heavy Industries
SHG:601106
|
China | CN¥31.77 Billion |
|
Iren S.p.A.
LSE:0MUN
|
UK | €6.95 Billion |
|
Jungheinrich Aktiengesellschaft
PINK:JGHAF
|
USA | $4.72 Billion |
|
Zhongsheng Group Holdings Limited
PINK:ZHSHF
|
USA | $60.25 Billion |
|
Himax Technologies Inc
NASDAQ:HIMX
|
USA | $832.88 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Zymeworks Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zymeworks Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual total liabilities of Zymeworks Inc. Common Stock from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $124.32 Million | +7.11% |
| 2023-12-31 | $116.07 Million | -25.48% |
| 2022-12-31 | $155.77 Million | +11.23% |
| 2021-12-31 | $140.04 Million | +9.02% |
| 2020-12-31 | $128.45 Million | +4.84% |
| 2019-12-31 | $122.52 Million | +91.82% |
| 2018-12-31 | $63.87 Million | +311.37% |
| 2017-12-31 | $15.53 Million | -81.73% |
| 2016-12-31 | $84.99 Million | +1631.02% |
| 2015-12-31 | $4.91 Million | -54.97% |
| 2014-12-31 | $10.90 Million | -- |